Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 3/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 9/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24193842 | 0.86 | ALPL (0.48) | ALPLRIPK1HDAC6KLKB1 | |
| SCHEMBL24193687 | 0.86 | ALPL (0.48) | ALPLRIPK1HDAC6KLKB1 | |
| SCHEMBL19224520 | 0.85 | NR1H2 (0.56) | ALPLRIPK1HDAC6NR1H2NR1H3 | |
| SCHEMBL23337455 | 0.84 | RIPK1 (0.41) | RIPK1KLKB1 | |
| SCHEMBL24812993 | 0.84 | HDAC6 (0.46) | ALPLRIPK1HDAC6NR1H2NR1H3 | |
| SCHEMBL23337254 | 0.82 | HCAR2 (0.58) | RIPK1KLKB1 | |
| SCHEMBL21776198 | 0.76 | RIPK1 (0.50) | ALPLRIPK1 | |
| SCHEMBL24167145 | 0.73 | NR1H2 (0.53) | ALPLRIPK1HDAC6NR1H2NR1H3 | |
| SCHEMBL23085471 | 0.73 | NR1H2 (0.53) | ALPLRIPK1HDAC6NR1H2NR1H3 | |
| SCHEMBL30848602 | 0.72 | NR1H2 (0.51) | ALPLRIPK1HDAC6NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20210214347-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| EP-3816163-A1 | CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2021-05-05 | — | — | EP | disclosed |
| US-10975064-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214347-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | ALPL 4226/4885RIPK1 1/4885HDAC6 1624/4885 |
| US-20240217958-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | ALPL 4226/4885RIPK1 1/4885HDAC6 1624/4885 |
| US-10975064-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | ALPL 4226/4885RIPK1 1/4885HDAC6 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.